NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
National Institutes of Health Clinical Center (CC)
Rain Oncology Inc
Jonsson Comprehensive Cancer Center
University of Chicago
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Southern California
University College, London